- Home
- BCO vs RYTM Comparison
BCO vs RYTM Comparison
Compare BCO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCO
- RYTM
- Stock Information
- Founded
- BCO 1859
- RYTM 2008
- Country
- BCO United States
- RYTM United States
- Employees
- BCO N/A
- RYTM N/A
- Industry
- BCO Oil Refining/Marketing
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BCO Consumer Discretionary
- RYTM Health Care
- Exchange
- BCO Nasdaq
- RYTM Nasdaq
- Market Cap
- BCO 3.7B
- RYTM 3.8B
- IPO Year
- BCO N/A
- RYTM 2017
- Fundamental
- Price
- BCO $87.54
- RYTM $61.74
- Analyst Decision
- BCO Strong Buy
- RYTM Strong Buy
- Analyst Count
- BCO 2
- RYTM 12
- Target Price
- BCO $138.00
- RYTM $74.92
- AVG Volume (30 Days)
- BCO 427.5K
- RYTM 940.6K
- Earning Date
- BCO 05-07-2025
- RYTM 05-06-2025
- Dividend Yield
- BCO 1.11%
- RYTM N/A
- EPS Growth
- BCO 94.75
- RYTM N/A
- EPS
- BCO 3.63
- RYTM N/A
- Revenue
- BCO $5,011,900,000.00
- RYTM $130,126,000.00
- Revenue This Year
- BCO $0.70
- RYTM $43.84
- Revenue Next Year
- BCO $4.60
- RYTM $65.62
- P/E Ratio
- BCO $24.25
- RYTM N/A
- Revenue Growth
- BCO 2.82
- RYTM 68.06
- 52 Week Low
- BCO $80.21
- RYTM $35.17
- 52 Week High
- BCO $115.91
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- BCO 51.12
- RYTM 61.94
- Support Level
- BCO $85.23
- RYTM $59.54
- Resistance Level
- BCO $88.35
- RYTM $62.83
- Average True Range (ATR)
- BCO 3.65
- RYTM 4.27
- MACD
- BCO 0.32
- RYTM 1.00
- Stochastic Oscillator
- BCO 69.41
- RYTM 92.04
About BCO Brinks Company (The)
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provides BGS services and BGS activity in Latin American countries. It derives maximum revenue from North America segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.